Estimated launch time and market prospects of Krazati in the country

Adagrasib (Krazati) is an innovative targeted drug targeting KRAS G12C mutation, which is of great significance in the field of precision treatment of lung cancer. Currently, the drug has been approved for marketing in the United States and is suitable for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed despite previous systemic treatment. KRAS G12CMutation accounts for a certain proportion of lung cancer patients in China, so the introduction of adagrasib has attracted much attention. As my country's demand for KRAS mutation treatment increases, the clinical value and potential market of this drug are gradually emerging.

As of now, adagrasib has not been approved for marketing in China, and patients who need to use it can only purchase it through regular overseas channels. In terms of price, the American version of the original drug is very expensive, up to hundreds of thousands of yuan per box, which is a heavy financial burden for most patients. The relatively cheaper version is the generic version produced in Laos, which costs about more than 3,000 yuan per box. The ingredients of the drug are basically the same as the original drug, so it has certain practical feasibility among some patient groups. However, when purchasing drugs overseas, you need to go through formal channels to avoid buying fake or substandard drugs.

From the perspective of the marketing process, international clinical trials and real-world data of adagrasib are constantly accumulating, and China’s introduction approval is also progressing. It is generally predicted in the industry that the drug is expected to complete marketing approval in China within the next few years. Once approved, it will provide more treatment options for patients with KRAS G12C mutated lung cancer, and may also change the current treatment pattern of chemotherapy or immunotherapy, further promoting the development of precision medicine in my country.

In the future, with the launch of adagrasib in China and the gradual improvement of medical insurance policies, drug prices are expected to drop and patients' medication burden will also be reduced. At the same time, if domestically produced or generic versions are launched in the future, the accessibility and cost-effectiveness of the drug will be further improved. Overall, adagrasib has broad prospects in the domestic market, and its clinical application value and economic significance are worth looking forward to.

Reference materials:https://www.drugs.com/